文献速递糖尿病

英格兰1型和2型糖尿病患者COVID-19相关死亡的危险因素:一项基于人群的队列研究

Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study.
PubMed 文献 · Lancet Diabetes Endocrinol · 2020-08-13

该研究基于英格兰国家糖尿病审计与死亡登记数据,分析2020年2月16日至5月11日1型和2型糖尿病患者COVID-19相关死亡的危险因素。结果显示,男性、高龄、肾功能受损、非白人 ethnicity、社会经济剥夺、既往卒中及心力衰竭与两类糖尿病COVID-19死亡风险增加相关;HbA1c≥86 mmol/mol及BMI呈U型关联亦为独立危险因素。

要点

  • 男性、高龄、肾功能受损、非白人 ethnicity、社会经济剥夺、既往卒中及心力衰竭与1型和2型糖尿病COVID-19死亡风险增加相关。
  • 与HbA1c 48-53 mmol/mol相比,HbA1c≥86 mmol/mol者1型糖尿病HR 2.23,2型糖尿病HR 1.61。
  • BMI与COVID-19死亡呈U型关联,1型糖尿病BMI<20.0 kg/m²的HR 2.45,BMI≥40.0 kg/m²的HR 2.33。

核心结论

  • 英格兰COVID-19大流行初期,1型和2型糖尿病患者的死亡人数急剧上升。
  • COVID-19相关死亡风险增加不仅与糖尿病的心血管和肾脏并发症相关,还独立与血糖控制和BMI相关。

研究设计与样本

  • 基于人群的队列研究,纳入英格兰全科诊所注册的已诊断1型和2型糖尿病患者。
  • 国家糖尿病审计数据与2017年1月2日至2020年5月11日死亡登记数据链接,采用Cox比例风险模型分析2020年2月16日至5月11日期间危险因素与COVID-19相关死亡的关联。

主要发现

  • 2020年前19周每周死亡登记数较2017-19年对应3年周均值增加:1型糖尿病672例(50.9%),2型糖尿病16 071例(64.3%)。
  • 2020年2月16日至5月11日,264 390例1型糖尿病患者中1604例全因死亡,其中464例为COVID-19相关;2 874 020例2型糖尿病患者中36 291例全因死亡,其中10 525例为COVID-19相关。
  • 1型糖尿病COVID-19相关死亡中289例(62.3%)、2型糖尿病中5833例(55.4%)发生于有心血管疾病史或肾功能受损(eGFR<60 mL/min per 1.73 m²)者。
  • 与HbA1c 48-53 mmol/mol(6.5-7.0%)相比,HbA1c≥86 mmol/mol(10.0%)者COVID-19相关死亡风险增加:1型糖尿病HR 2.23(95%CI 1.50-3.30,p<0.0001),2型糖尿病HR 1.61(95%CI 1.47-1.77,p<0.0001)。
  • 2型糖尿病中,与HbA1c 48-53 mmol/mol相比,HbA1c 59-74 mmol/mol(7.6-8.9%)的HR 1.22(95%CI 1.15-1.30,p<0.0001),HbA1c 75-85 mmol/mol(9.0-9.9%)的HR 1.36(95%CI 1.24-1.50,p<0.0001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diabetes has been associated with increased COVID-19-related mortality, but the association between modifiable risk factors, including hyperglycaemia and obesity, and COVID-19-related mortality among people with diabetes is unclear. We assessed associations between risk factors and COVID-19-related mortality in people with type 1 and type 2 diabetes. METHODS: We did a population-based cohort study of people with diagnosed diabetes who were registered with a general practice in England. National population data on people with type 1 and type 2 diabetes collated by the National Diabetes Audit were linked to mortality records collated by the Office for National Statistics from Jan 2, 2017, to May 11, 2020. We identified the weekly number of deaths in people with type 1 and type 2 diabetes during the first 19 weeks of 2020 and calculated the percentage change from the mean number of deaths for the corresponding weeks in 2017, 2018, and 2019. The associations between risk factors (including sex, age, ethnicity, socioeconomic deprivation, HbA1c, renal impairment [from estimated glomerular filtration rate (eGFR)], BMI, tobacco smoking status, and cardiovascular comorbidities) and COVID-19-related mortality (defined as International Classification of Diseases, version 10, code U07.1 or U07.2 as a primary or secondary cause of death) between Feb 16 and May 11, 2020, were investigated by use of Cox proportional hazards models. FINDINGS: Weekly death registrations in the first 19 weeks of 2020 exceeded the corresponding 3-year weekly averages for 2017-19 by 672 (50·9%) in people with type 1 diabetes and 16 071 (64·3%) in people with type 2 diabetes. Between Feb 16 and May 11, 2020, among 264 390 people with type 1 diabetes and 2 874 020 people with type 2 diabetes, 1604 people with type 1 diabetes and 36 291 people with type 2 diabetes died from all causes. Of these total deaths, 464 in people with type 1 diabetes and 10 525 in people with type 2 diabetes were defined as COVID-19 related, of which 289 (62·3%) and 5833 (55·4%), respectively, occurred in people with a history of cardiovascular disease or with renal impairment (eGFR <60 mL/min per 1·73 m2). Male sex, older age, renal impairment, non-white ethnicity, socioeconomic deprivation, and previous stroke and heart failure were associated with increased COVID-19-related mortality in both type 1 and type 2 diabetes. Compared with people with an HbA1c of 48-53 mmol/mol (6·5-7·0%), people with an HbA1c of 86 mmol/mol (10·0%) or higher had increased COVID-19-related mortality (hazard ratio [HR] 2·23 [95% CI 1·50-3·30, p<0·0001] in type 1 diabetes and 1·61 [1·47-1·77, p<0·0001] in type 2 diabetes). In addition, in people with type 2 diabetes, COVID-19-related mortality was significantly higher in those with an HbA1c of 59 mmol/mol (7·6%) or higher than in those with an HbA1c of 48-53 mmol/mol (HR 1·22 [95% CI 1·15-1·30, p<0·0001] for 59-74 mmol/mol [7·6-8·9%] and 1·36 [1·24-1·50, p<0·0001] for 75-85 mmol/mol [9·0-9·9%]). The association between BMI and COVID-19-related mortality was U-shaped: in type 1 diabetes, compared with a BMI of 25·0-29·9 kg/m2, a BMI of less than 20·0 kg/m2 had an HR of 2·45 (95% CI 1·60-3·75, p<0·0001) and a BMI of 40·0 kg/m2 or higher had an HR of 2·33 (1·53-3·56, p<0·0001); the corresponding HRs for type 2 diabetes were 2·33 (2·11-2·56, p<0·0001) and 1·60 (1·47-1·75, p<0·0001). INTERPRETATION: Deaths in people with type 1 and type 2 diabetes rose sharply during the initial COVID-19 pandemic in England. Increased COVID-19-related mortality was associated not only with cardiovascular and renal complications of diabetes but, independently, also with glycaemic control and BMI. FUNDING: None.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020. PMID: 32798471. doi:10.1016/S2213-8587(20)30271-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。